請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22958完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 呂紹俊(Shao-Chun Lu) | |
| dc.contributor.author | Yu-Sheng Lai | en |
| dc.contributor.author | 賴昱昇 | zh_TW |
| dc.date.accessioned | 2021-06-08T04:35:14Z | - |
| dc.date.copyright | 2009-09-15 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-08-18 | |
| dc.identifier.citation | (2001). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486-2497.
Abu-Elheiga, L., Matzuk, M.M., Abo-Hashema, K.A., and Wakil, S.J. (2001). Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291, 2613-2616. Ahmed, R.A., Murao, K., Imachi, H., Yu, X., Li, J., Wong, N.C., and Ishida, T. (2009). Human scavenger receptor class B type 1 is regulated by activators of peroxisome proliferators-activated receptor-gamma in hepatocytes. Endocrine 35, 233-242. Amarapurkar, D., Kamani, P., Patel, N., Gupte, P., Kumar, P., Agal, S., Baijal, R., Lala, S., Chaudhary, D., and Deshpande, A. (2007). Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 6, 161-163. Angulo, P. (2002). Nonalcoholic fatty liver disease. N Engl J Med 346, 1221-1231. Anstee, Q.M., and Goldin, R.D. (2006). Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87, 1-16. Asai, A., and Miyazawa, T. (2001). Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 131, 2932-2935. Assy, N., Hussein, O., and Abassi, Z. (2007). Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 56, 443-444. Bardot, O., Aldridge, T.C., Latruffe, N., and Green, S. (1993). PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun 192, 37-45. Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006). A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355, 2297-2307. Brown, M.S., and Goldstein, J.L. (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340. Brown, M.S., and Goldstein, J.L. (1999). A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A 96, 11041-11048. Browning, J.D., and Horton, J.D. (2004). Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114, 147-152. Brusq, J.M., Ancellin, N., Grondin, P., Guillard, R., Martin, S., Saintillan, Y., and Issandou, M. (2006). Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47, 1281-1288. Bugianesi, E., Gastaldelli, A., Vanni, E., Gambino, R., Cassader, M., Baldi, S., Ponti, V., Pagano, G., Ferrannini, E., and Rizzetto, M. (2005). Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48, 634-642. Castro, J., Amigo, L., Miquel, J.F., Galman, C., Crovari, F., Raddatz, A., Zanlungo, S., Jalil, R., Rudling, M., and Nervi, F. (2007). Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease. Hepatology 45, 1261-1266. Cavelier, C., Lorenzi, I., Rohrer, L., and von Eckardstein, A. (2006). Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta 1761, 655-666. Chakravarthy, M.V., Pan, Z., Zhu, Y., Tordjman, K., Schneider, J.G., Coleman, T., Turk, J., and Semenkovich, C.F. (2005). 'New' hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab 1, 309-322. Chalasani, N., Gorski, J.C., Asghar, M.S., Asghar, A., Foresman, B., Hall, S.D., and Crabb, D.W. (2003). Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37, 544-550. Chiu, P.Y., Tang, M.H., Mak, D.H., Poon, M.K., and Ko, K.M. (2003). Hepatoprotective mechanism of schisandrin B: role of mitochondrial glutathione antioxidant status and heat shock proteins. Free Radic Biol Med 35, 368-380. Clark, J.M., and Diehl, A.M. (2003). Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 124, 248-250. Cong, W.N., Tao, R.Y., Tian, J.Y., Liu, G.T., and Ye, F. (2008). The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci 82, 983-990. Crespo, J., Cayon, A., Fernandez-Gil, P., Hernandez-Guerra, M., Mayorga, M., Dominguez-Diez, A., Fernandez-Escalante, J.C., and Pons-Romero, F. (2001). Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34, 1158-1163. Cummings, M.H., Watts, G.F., Umpleby, A.M., Hennessy, T.R., Kelly, J.M., Jackson, N.C., and Sonksen, P.H. (1995). Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 44, 1059-1065. Davis, R.A., McNeal, M.M., and Moses, R.L. (1982). Intrahepatic assembly of very low density lipoprotein. Competition by cholesterol esters for the hydrophobic core. J Biol Chem 257, 2634-2640. Day, C.P. (2006). From fat to inflammation. Gastroenterology 130, 207-210. Dentin, R., Benhamed, F., Hainault, I., Fauveau, V., Foufelle, F., Dyck, J.R., Girard, J., and Postic, C. (2006a). Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 55, 2159-2170. Dentin, R., Denechaud, P.D., Benhamed, F., Girard, J., and Postic, C. (2006b). Hepatic gene regulation by glucose and polyunsaturated fatty acids: a role for ChREBP. J Nutr 136, 1145-1149. Dentin, R., Girard, J., and Postic, C. (2005). Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 87, 81-86. Despres, J.P., and Lemieux, I. (2006). Abdominal obesity and metabolic syndrome. Nature 444, 881-887. Diehl, A.M., Li, Z.P., Lin, H.Z., and Yang, S.Q. (2005). Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54, 303-306. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., and Parks, E.J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115, 1343-1351. Fan, C.Y., Pan, J., Usuda, N., Yeldandi, A.V., Rao, M.S., and Reddy, J.K. (1998). Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J Biol Chem 273, 15639-15645. Fan, J.G. (2004). Evaluating the efficacy and safety of Danning Pian in the short-term treatment of patients with non-alcoholic fatty liver disease: a multicenter clinical trial. Hepatobiliary Pancreat Dis Int 3, 375-380. Farrell, G.C. (2005). Fatty liver disease : NASH and related disorders (Malden, Mass., Blackwell Pub.). Farrell, G.C., and Larter, C.Z. (2006). Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112. Fernandes-Santos, C., Carneiro, R.E., Mendonca, L.D., Aguila, M.B., and Mandarim-de-Lacerda, C.A. (2009). Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet. Nutrition. Goodwin, B., Watson, M.A., Kim, H., Miao, J., Kemper, J.K., and Kliewer, S.A. (2003). Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol Endocrinol 17, 386-394. Grefhorst, A., Elzinga, B.M., Voshol, P.J., Plosch, T., Kok, T., Bloks, V.W., van der Sluijs, F.H., Havekes, L.M., Romijn, J.A., Verkade, H.J., et al. (2002). Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277, 34182-34190. Grum, D.E., Hansen, L.R., and Drackley, J.K. (1994). Peroxisomal beta-oxidation of fatty acids in bovine and rat liver. Comp Biochem Physiol B Biochem Mol Biol 109, 281-292. Guo, L.Y., Hung, T.M., Bae, K.H., Shin, E.M., Zhou, H.Y., Hong, Y.N., Kang, S.S., Kim, H.P., and Kim, Y.S. (2008). Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. Eur J Pharmacol 591, 293-299. Hamaguchi, M., Kojima, T., Takeda, N., Nakagawa, T., Taniguchi, H., Fujii, K., Omatsu, T., Nakajima, T., Sarui, H., Shimazaki, M., et al. (2005). The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143, 722-728. Harano, Y., Yasui, K., Toyama, T., Nakajima, T., Mitsuyoshi, H., Mimani, M., Hirasawa, T., Itoh, Y., and Okanoue, T. (2006). Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 26, 613-620. Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I., and Terano, A. (2001). Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15, 1667-1672. Hashimoto, T., Fujita, T., Usuda, N., Cook, W., Qi, C., Peters, J.M., Gonzalez, F.J., Yeldandi, A.V., Rao, M.S., and Reddy, J.K. (1999). Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem 274, 19228-19236. Haukeland, J.W., Damas, J.K., Konopski, Z., Loberg, E.M., Haaland, T., Goverud, I., Torjesen, P.A., Birkeland, K., Bjoro, K., and Aukrust, P. (2006). Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44, 1167-1174. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C.Z., Uysal, K.T., Maeda, K., Karin, M., and Hotamisligil, G.S. (2002). A central role for JNK in obesity and insulin resistance. Nature 420, 333-336. Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004). Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113, 1774-1783. Hua, X., Wu, J., Goldstein, J.L., Brown, M.S., and Hobbs, H.H. (1995). Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics 25, 667-673. Hui, J.M., Hodge, A., Farrell, G.C., Kench, J.G., Kriketos, A., and George, J. (2004). Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40, 46-54. Iizuka, K., Bruick, R.K., Liang, G., Horton, J.D., and Uyeda, K. (2004). Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A 101, 7281-7286. Ip, E., Farrell, G., Hall, P., Robertson, G., and Leclercq, I. (2004). Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39, 1286-1296. Ito, M., Suzuki, J., Tsujioka, S., Sasaki, M., Gomori, A., Shirakura, T., Hirose, H., Ishihara, A., Iwaasa, H., and Kanatani, A. (2007). Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol Res 37, 50-57. Jiang, W.X., and Xue, B.Y. (2005). [Hepatoprotective effects of Gentiana scabra on the acute liver injuries in mice]. Zhongguo Zhong Yao Za Zhi 30, 1105-1107. Joseph, S.B., McKilligin, E., Pei, L., Watson, M.A., Collins, A.R., Laffitte, B.A., Chen, M., Noh, G., Goodman, J., Hagger, G.N., et al. (2002). Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A 99, 7604-7609. Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K., et al. (2006). MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116, 1494-1505. Kim, Y.W., Ki, S.H., Lee, J.R., Lee, S.J., Kim, C.W., Kim, S.C., and Kim, S.G. (2006). Liquiritigenin, an aglycone of liquiritin in Glycyrrhizae radix, prevents acute liver injuries in rats induced by acetaminophen with or without buthionine sulfoximine. Chem Biol Interact 161, 125-138. Knobler, H., Schattner, A., Zhornicki, T., Malnick, S.D., Keter, D., Sokolovskaya, N., Lurie, Y., and Bass, D.D. (1999). Fatty liver--an additional and treatable feature of the insulin resistance syndrome. QJM 92, 73-79. Koteish, A., and Diehl, A.M. (2001). Animal models of steatosis. Semin Liver Dis 21, 89-104. Kugelmas, M., Hill, D.B., Vivian, B., Marsano, L., and McClain, C.J. (2003). Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38, 413-419. Larter, C.Z., and Farrell, G.C. (2006). Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol 44, 253-261. Larter, C.Z., and Yeh, M.M. (2008). Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23, 1635-1648. Leclercq, I.A., Farrell, G.C., Schriemer, R., and Robertson, G.R. (2002). Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37, 206-213. Leevy, C.M. (1962). Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine (Baltimore) 41, 249-276. Lehmann, J.M., Kliewer, S.A., Moore, L.B., Smith-Oliver, T.A., Oliver, B.B., Su, J.L., Sundseth, S.S., Winegar, D.A., Blanchard, D.E., Spencer, T.A., et al. (1997). Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem 272, 3137-3140. Letteron, P., Sutton, A., Mansouri, A., Fromenty, B., and Pessayre, D. (2003). Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 38, 133-140. Levy, J.R., Clore, J.N., and Stevens, W. (2004). Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 39, 608-616. Lewis, G.F., Carpentier, A., Adeli, K., and Giacca, A. (2002). Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23, 201-229. Lewis, G.F., Uffelman, K.D., Szeto, L.W., and Steiner, G. (1993). Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42, 833-842. Lieber, C.S., Leo, M.A., Mak, K.M., Xu, Y., Cao, Q., Ren, C., Ponomarenko, A., and DeCarli, L.M. (2004). Model of nonalcoholic steatohepatitis. Am J Clin Nutr 79, 502-509. Lin, S.C., Lin, C.C., Lu, F.J., Lin, Y.H., and Chen, C.H. (1996). Protective and therapeutic effects of huanglian-jie-du-tang on hepatotoxin-induced liver injuries. Am J Chin Med 24, 219-229. London, R.M., and George, J. (2007). Pathogenesis of NASH: animal models. Clin Liver Dis 11, 55-74, viii. Louet, J.F., Chatelain, F., Decaux, J.F., Park, E.A., Kohl, C., Pineau, T., Girard, J., and Pegorier, J.P. (2001). Long-chain fatty acids regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a peroxisome-proliferator-activated receptor alpha (PPARalpha)-independent pathway. Biochem J 354, 189-197. Lu, B., Xu, L., Yu, L., and Zhang, L. (2008). Extract of radix curcumae prevents gastric cancer in rats. Digestion 77, 87-91. Ludwig, A.M., Wikler, A., Buchsbaum, M., Cain, R.B., and Vannier, M.W. (1979). Similarity of effects of alcohol and sensory stimulation in post-alcoholics and controls. Alcohol Clin Exp Res 3, 248-251. Lutchman, G., Promrat, K., Kleiner, D.E., Heller, T., Ghany, M.G., Yanovski, J.A., Liang, T.J., and Hoofnagle, J.H. (2006). Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol 4, 1048-1052. Macdonald, G.A., and Prins, J.B. (2004). Peroxisomal fatty acid metabolism, peroxisomal proliferator-activated receptors and non-alcoholic fatty liver disease. J Gastroenterol Hepatol 19, 1335-1337. Mari, M., Caballero, F., Colell, A., Morales, A., Caballeria, J., Fernandez, A., Enrich, C., Fernandez-Checa, J.C., and Garcia-Ruiz, C. (2006). Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4, 185-198. Martinez-Chantar, M.L., Corrales, F.J., Martinez-Cruz, L.A., Garcia-Trevijano, E.R., Huang, Z.Z., Chen, L., Kanel, G., Avila, M.A., Mato, J.M., and Lu, S.C. (2002). Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J 16, 1292-1294. Mato, J.M., Martinez-Chantar, M.L., and Lu, S.C. (2008). Methionine metabolism and liver disease. Annu Rev Nutr 28, 273-293. Matsusue, K., Haluzik, M., Lambert, G., Yim, S.H., Gavrilova, O., Ward, J.M., Brewer, B., Jr., Reitman, M.L., and Gonzalez, F.J. (2003). Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 111, 737-747. Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., and McCullough, A.J. (1999). Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413-1419. Mitro, N., Mak, P.A., Vargas, L., Godio, C., Hampton, E., Molteni, V., Kreusch, A., and Saez, E. (2007). The nuclear receptor LXR is a glucose sensor. Nature 445, 219-223. Moro, T., Shimoyama, Y., Kushida, M., Hong, Y.Y., Nakao, S., Higashiyama, R., Sugioka, Y., Inoue, H., Okazaki, I., and Inagaki, Y. (2008). Glycyrrhizin and its metabolite inhibit Smad3-mediated type I collagen gene transcription and suppress experimental murine liver fibrosis. Life Sci 83, 531-539. Munday, M.R. (2002). Regulation of mammalian acetyl-CoA carboxylase. Biochem Soc Trans 30, 1059-1064. Musso, G., Gambino, R., and Cassader, M. (2009). Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48, 1-26. Nagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., and Shibata, N. (2006). Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536, 182-191. Nakamuta, M., Fujino, T., Yada, R., Yada, M., Yasutake, K., Yoshimoto, T., Harada, N., Higuchi, N., Kato, M., Kohjima, M., et al. (2009). Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease. Int J Mol Med 23, 603-608. Neuschwander-Tetri, B.A., Brunt, E.M., Wehmeier, K.R., Oliver, D., and Bacon, B.R. (2003). Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38, 1008-1017. Nissen, S.E., and Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356, 2457-2471. Oh, M.K., Winn, J., and Poordad, F. (2008). Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 28, 503-522. Oka, K., Kobayashi, K., Sullivan, M., Martinez, J., Teng, B.B., Ishimura-Oka, K., and Chan, L. (1997). Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus-mediated transfer of a dominant negative mutant APOBEC-1 leads to increased low density lipoprotein in mice. J Biol Chem 272, 1456-1460. Pan, S.Y., Dong, H., Zhao, X.Y., Xiang, C.J., Fang, H.Y., Fong, W.F., Yu, Z.L., and Ko, K.M. (2008). Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. J Pharm Pharmacol 60, 399-403. Paniagua, J.A., Gallego de la Sacristana, A., Romero, I., Vidal-Puig, A., Latre, J.M., Sanchez, E., Perez-Martinez, P., Lopez-Miranda, J., and Perez-Jimenez, F. (2007). Monounsaturated fat-rich diet prevents central body fat distribution and decreases postprandial adiponectin expression induced by a carbohydrate-rich diet in insulin-resistant subjects. Diabetes Care 30, 1717-1723. Parekh, S., and Anania, F.A. (2007). Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132, 2191-2207. Peschel, D., Koerting, R., and Nass, N. (2007). Curcumin induces changes in expression of genes involved in cholesterol homeostasis. J Nutr Biochem 18, 113-119. Poonawala, A., Nair, S.P., and Thuluvath, P.J. (2000). Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32, 689-692. Ratziu, V., and Poynard, T. (2006). Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious. Hepatology 44, 802-805. Reddy, J.K., and Hashimoto, T. (2001). Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr 21, 193-230. Rinella, M.E., Elias, M.S., Smolak, R.R., Fu, T., Borensztajn, J., and Green, R.M. (2008). Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 49, 1068-1076. Rinella, M.E., and Green, R.M. (2004). The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40, 47-51. Robertson, G., Leclercq, I., and Farrell, G.C. (2001). Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 281, G1135-1139. Sahai, A., Malladi, P., Pan, X., Paul, R., Melin-Aldana, H., Green, R.M., and Whitington, P.F. (2004). Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287, G1035-1043. Sanal, M.G. (2008). The blind men 'see' the elephant-the many faces of fatty liver disease. World J Gastroenterol 14, 831-844. Savage, D.B., Choi, C.S., Samuel, V.T., Liu, Z.X., Zhang, D., Wang, A., Zhang, X.M., Cline, G.W., Yu, X.X., Geisler, J.G., et al. (2006). Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 116, 817-824. Savage, D.B., Tan, G.D., Acerini, C.L., Jebb, S.A., Agostini, M., Gurnell, M., Williams, R.L., Umpleby, A.M., Thomas, E.L., Bell, J.D., et al. (2003). Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52, 910-917. Schattenberg, J.M., Wang, Y., Singh, R., Rigoli, R.M., and Czaja, M.J. (2005). Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 280, 9887-9894. Schultz, J.R., Tu, H., Luk, A., Repa, J.J., Medina, J.C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D.J., et al. (2000). Role of LXRs in control of lipogenesis. Genes Dev 14, 2831-2838. Sekiya, M., Yahagi, N., Matsuzaka, T., Najima, Y., Nakakuki, M., Nagai, R., Ishibashi, S., Osuga, J., Yamada, N., and Shimano, H. (2003). Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38, 1529-1539. She, H., Xiong, S., Hazra, S., and Tsukamoto, H. (2005). Adipogenic transcriptional regulation of hepatic stellate cells. J Biol Chem 280, 4959-4967. Shimano, H., Horton, J.D., Shimomura, I., Hammer, R.E., Brown, M.S., and Goldstein, J.L. (1997). Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99, 846-854. Shimomura, I., Bashmakov, Y., and Horton, J.D. (1999). Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274, 30028-30032. Shimomura, I., Matsuda, M., Hammer, R.E., Bashmakov, Y., Brown, M.S., and Goldstein, J.L. (2000). Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6, 77-86. Shimomura, I., Shimano, H., Horton, J.D., Goldstein, J.L., and Brown, M.S. (1997). Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99, 838-845. Sreejayan, and Rao, M.N. (1994). Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol 46, 1013-1016. Tamura, S., and Shimomura, I. (2005). Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 115, 1139-1142. Tilg, H., and Diehl, A.M. (2000). Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343, 1467-1476. Tilg, H., and Moschen, A.R. (2008). Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 19, 371-379. Timlin, M.T., and Parks, E.J. (2005). Temporal pattern of de novo lipogenesis in the postprandial state in healthy men. Am J Clin Nutr 81, 35-42. Torres, D.M., and Harrison, S.A. (2008). Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134, 1682-1698. Tulenko, T.N., and Sumner, A.E. (2002). The physiology of lipoproteins. J Nucl Cardiol 9, 638-649. Unger, R.H., and Orci, L. (2002). Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 1585, 202-212. Vergnes, L., Phan, J., Strauss, M., Tafuri, S., and Reue, K. (2003). Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression. J Biol Chem 278, 42774-42784. Vianey-Saban, C., Mousson, B., Bertrand, C., Stamm, D., Dumoulin, R., Zabot, M.T., Divry, P., Floret, D., and Mathieu, M. (1993). Carnitine palmitoyl transferase I deficiency presenting as a Reye-like syndrome without hypoglycaemia. Eur J Pediatr 152, 334-338. Wang, D., Wei, Y., and Pagliassotti, M.J. (2006). Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 147, 943-951. Winzell, M.S., and Ahren, B. (2004). The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 Suppl 3, S215-219. Wouters, K., van Gorp, P.J., Bieghs, V., Gijbels, M.J., Duimel, H., Lutjohann, D., Kerksiek, A., van Kruchten, R., Maeda, N., Staels, B., et al. (2008). Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48, 474-486. Wu, X., Zhang, L., Gurley, E., Studer, E., Shang, J., Wang, T., Wang, C., Yan, M., Jiang, Z., Hylemon, P.B., et al. (2008). Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 47, 1905-1915. Yahagi, N., Shimano, H., Hasty, A.H., Matsuzaka, T., Ide, T., Yoshikawa, T., Amemiya-Kudo, M., Tomita, S., Okazaki, H., Tamura, Y., et al. (2002). Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277, 19353-19357. Yamada, S., Murawaki, Y., and Kawasaki, H. (1993). Preventive effect of gomisin A, a lignan component of shizandra fruits, on acetaminophen-induced hepatotoxicity in rats. Biochem Pharmacol 46, 1081-1085. Yancy, W.S., Jr., Olsen, M.K., Guyton, J.R., Bakst, R.P., and Westman, E.C. (2004). A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 140, 769-777. Yang, S.Q., Lin, H.Z., Lane, M.D., Clemens, M., and Diehl, A.M. (1997). Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 94, 2557-2562. 台灣原住民藥用植物彙編 (2002)行政院中醫藥委員會，發行人：林宜信主任委員，主編：張永勳教授。 台灣常用藥用植物圖鑑 (2006) (Vol. I、Vol. II、Vol III) 行政院中醫藥委員會，發行人：林宜信主任委員，主編：謝文全教授。 翁啟書 (2008) 探討黃連解毒湯與柴胡舒肝湯於HepG2細胞及三個非酒精性脂肪肝小鼠模式之作用。國立台灣大學醫學院生物化學暨分子生物學研究所碩士論文 郝立智 柴國樑 (2004) 漫談脂肪肝。台灣醫學雜誌，第47卷第1期 劉娟秀 (1992) 膽固醇性脂肪肝機轉之研究。國立台灣大學醫學院生化學研究所博士論文 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22958 | - |
| dc.description.abstract | 非酒精性脂肪肝，定義為非酗酒過量者之肝細胞脂肪重量達到肝總重5%以上。致病原因可歸納於脂肪酸合成增加及 (或) 脂肪酸分解減低。近年來國內成人人口脂肪肝盛行率高達26-34%。臨床研究顯示非酒精性脂肪肝與肥胖、糖尿病及代謝症候群相關疾病有高度正相關。此外，近年研究更顯示，非酒精性脂肪肝有相當比例發展成肝纖維化、肝硬化甚至是肝癌。然而目前臨床上並無令人滿意的藥物，因此使得非酒精性脂肪乾的治療藥物開發有相當的空間。
我們從中醫古籍上記載具有保肝功能之中藥篩選可降低細胞三酸甘油酯的中草藥，由18種複方即60種單方中草藥中，我們篩選出可降低細胞三酸甘油酯的5種複方及18種單方，並探討其用於治療非酒精性脂肪肝的可能性。 首先我們以LXR agonist—T0901317存在與否發現有2種複方可降低HepG2細胞中三酸甘油酯含量。之後以西方點墨法發現22種單方中有13種單方降低細胞中FASN蛋白含量，顯示這些藥材具有抑制脂肪酸合成的功效。接著以intralipid直接提供脂肪酸來源並抑制脂肪酸合成，發現有3種單方仍可降低肝細胞TG顯示可能具促進脂肪酸氧化分解的作用。經由中醫師之建議，將上述篩選出可抑制脂肪酸合成與促進分解之中草藥單方組成兩個配方：A配方及B配方。 之後我們以十一週大C57BL/6雌性小鼠為動物模式，將之分為四組，分別為控制組、Lipogenic diet組 (35% corn starch + 35% sucrose)、Lipogenic diet + A配方組與Lipogenic diet + B配方組。飼養8週後，灌食B配方可顯著降低肝臟總膽固醇含量，也減低腹腔脂肪重量，肝組織切片亦發現脂肪空泡堆積明顯減少之情形。然而各組間血液AST與ALT活性並無顯著差異，但由RT-qPCR分析發炎反應基因，發現比起控制組餵食Lipogenic diet顯著增加MCP-1、F4/80及TNF-α表現，而灌食B配方可顯著抑制餵食Lipogenic diet引發MCP-1、F4/80及TNF-α之mRNA表現。另外， Lipogenic diet組織SREBP-1 mRNA表現顯著高於控制組，但灌食B配方可顯著降低其表現；而CPT-1a與ACO在餵食Lipogenic diet後表現顯著低於控制組，灌食A配方及B配方皆可提升其表現量。顯示此動物模式下，B配方可影響全身性脂肪之代謝同時抑制肝臟發炎現象，然而A配方雖可改善肝臟脂肪堆積但未抑制發炎反應。 動物實驗結果發現B配方具有改善肝臟脂肪堆積與降低發炎指標之功效，然而B配方是否在其他動物模式仍然有效還有待後續實驗分析，因此如何以不同動物模式印證B配方之效果，找出B配方之有效成分及其作用機轉為日後後續研究之重點。 | zh_TW |
| dc.description.abstract | Non-alcoholic fatty liver disease (NAFLD) is a disease with over 5% fat (w/w) in the liver of people who consumed limited amount of alcohol. The pathology of NAFLD can be resulted from the increase of fatty acid synthesis and/or decrease of fatty acid β-oxidation. The prevalence of NAFLD in Taiwan is about 26-34%. Clinical and epidemiological studies revealed that NAFLD is associated with metabolic syndrome, such as insulin resistance and obesity. Furthermore, NAFLD is predicted as a risk factor of liver fibrosis, cirrhosis and cancer. Still, there is no satisfying medicines to treat NAFLD. Thus, it makes developing of medicines for treatment of NAFLD more important.
We screened a total of 60 Chinese Herbal Medicines (CHMs) in HepG2 for their effects on cellular triacylglycerol (TG). Five CHM prescriptions were identified, which could decrease cellular TG in the presence or absence of LXR agonist – T0901317. Twenty-two CHMs were identified could decrease cellular TG for at least 20%. Western blot and RT-PCR showed that 13 of these CHMs could inhibited fatty acid synthase (FASN) expression and three of them could increase fatty acid oxidation. Two mixtures, mixture A and B, that contained CHMs could inhibit FASN, and the CHMs which could induce FA oxidation were prepared according to the suggestion of doctors of traditional Chinese medicine. An animal experiment was carried out using 11-week old C57BL/6 female mice. Mice were divided into four groups: control, lipogenic diet, lipogenic diet + mixture A and lipogenic diet + mixture B, mixtures A and B were given by gavage. After 8 weeks of treatment, mixture B significantly decreased hepatic content of total cholesterol and the weight of abdominal fat. Histological analysis showed that mixture B improved liver steatosis signifcantly. No difference was found in the plasma AST and ALT activities among four groups. However, RT-Q-PCR analysis revealed that feeding lipogenic diet induce increased mRNA levels of macrophage infiltration and hepatic inflammatory cytokines, such as MCP-1, F4/80 and TNF- | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T04:35:14Z (GMT). No. of bitstreams: 1 ntu-98-R96442023-1.pdf: 1499760 bytes, checksum: 209ad27cdd162cb86b222d24972c059d (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 摘要 iii
Abstract v 縮寫對照表 vii 第一章、緒論 1 第一節、文獻回顧 2 第二節 研究動機與實驗目的 12 第二章、材料與方法 14 第一節、實驗材料 15 第二節、藥品配製 16 第三節、細胞實驗 19 第四節、動物實驗 22 第五節、統計分析 27 第三章、實驗結果 28 第一節、HepG2細胞實驗 29 第二節、C57BL/6雌性小鼠動物實驗 30 第四章、圖表 34 第五章、討論 50 第一節、總結 51 第二節、細胞實驗 51 第三節、動物實驗 53 第四節、A配方與B配方治療潛力 59 參考文獻： 62 | |
| dc.language.iso | zh-TW | |
| dc.subject | 非酒精性脂肪肝 | zh_TW |
| dc.subject | 三酸甘油酯 | zh_TW |
| dc.subject | 肝發炎反應 | zh_TW |
| dc.subject | 中草藥 | zh_TW |
| dc.subject | Chinese Herbal Medicine | en |
| dc.subject | hepatic inflammation | en |
| dc.subject | triglyceride | en |
| dc.subject | NAFLD | en |
| dc.title | 具有治療非酒精性脂肪肝之中草藥之篩選 | zh_TW |
| dc.title | Identification of Chinese herbal medicines for treatment of nonalcoholic fatty liver disease | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林榮耀(Jung-Yaw Lin),吳永昌(Yang-Chang Wu),方剛(Kang Fang) | |
| dc.subject.keyword | 非酒精性脂肪肝,三酸甘油酯,肝發炎反應,中草藥, | zh_TW |
| dc.subject.keyword | NAFLD,triglyceride,hepatic inflammation,Chinese Herbal Medicine, | en |
| dc.relation.page | 81 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2009-08-18 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
| 顯示於系所單位： | 生物化學暨分子生物學科研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 1.46 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。